Prescribing BROVANA® (arformoterol tartrate)

Dr. Smith's Dashboard

Sunovion Services

Request complimentary samples of BROVANA® (arformoterol tartrate) Inhalation Solution for your patients



Need support for your patients? Ask Sunovion Answers for information about BROVANA® (arformoterol tartrate)


A dedicated team is available between 8 AM and 8 PM ET, Monday through Friday, to answer calls at 1-844-276-8262



Most Viewed

Prescribing BROVANA

Prescribing nebulized BROVANA® (arformoterol tartrate) Inhalation Solution for patients with different types of coverage

Medicare Part B
Outpatient and Assisted Living Settings

BROVANA is covered under Medicare Part B; prior use of short-acting beta-agonists (SABAs) is no longer required.*
See the Guide >

Medicare Part A
Hospital, Skilled-Nursing, LTAC (Long-Term Acute Care) Facilities

BROVANA may be covered under Medicare Part A for Hospital, LTAC and Skilled-Nursing facilities.*

Medicare Part D
Long-Term Care Settings

BROVANA may be covered under Medicare Part D for Long-Term Care.*

Medicare Part C
Medicare Advantage Plans

BROVANA may be covered under Medicare Part C; these Medicare Advantage Plans may or may not include pharmacy benefits.*

*No guarantee of coverage.

Prescription Requirements for Medicare Patients

New patients need 2 separate prescriptions and a detailed written order*

When prescribing BROVANA for Medicare patients new to nebulized therapy, include the following:

1) A prescription for BROVANA

Be sure to specify:

• Dosing instructions

• "By nebulizer"

• Number of refills

• ICD code(s)



2) A prescription for a nebulizer

Be sure to specify:

• Compressor-E0570

• Administration set-A7005

• Mask-A7015



3) Detailed written order1

Medicare requires a physician to document that a face-to-face encounter/examination with the patient, detailing the treatment and/or evaluation of a condition that supports the need for the nebulizer, occurred within the 6 months prior to the written order for a nebulizer.

• A copy of this face-to-face encounter must be signed and dated by the physician; only physicians with a National Provider Identifier (NPI) can sign the prescription

• The date of the written order must not be prior to the date of the face-to-face encounter

Always include the beneficiary’s name, item of durable medication equipment (DME) ordered, and prescribing practitioner’s NPI. 

*No guarantee of coverage.
DME suppliers may require additional documentation.

Need support? Ask Sunovion Answers.

If your patients have questions about reimbursement, give them Sunovion Answers—a dedicated support service for BROVANA patients.


8 AM-8 AM ET, Monday-Friday

Important Safety Information & Indication

Important Safety Information


Long-acting beta2-adrenergic agonists (LABAs) increase the risk of asthma-related death. Data from a large placebo-controlled US study that compared the safety of another LABA (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of LABAs, including arformoterol, the active ingredient in BROVANA.

The safety and efficacy of BROVANA in patients with asthma have not been established. BROVANA is not indicated for the treatment of asthma.

All LABAs, including BROVANA, are contraindicated in patients with asthma without use of a long-term asthma control medication; BROVANA is also contraindicated in patients with a history of hypersensitivity to arformoterol, racemic formoterol or to any of the ingredients. 

BROVANA should not be initiated in patients with acutely deteriorating COPD or potentially life-threatening episodes of COPD, or used as rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

BROVANA should not be used more often, at higher doses than recommended, or in conjunction with other medications containing LABAs as an overdose may result. Patients who have been taking inhaled short-acting beta2-agonists on a regular basis should be instructed to discontinue their regular use and to use them only for symptomatic relief for acute respiratory symptoms. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. Patients using BROVANA should not use another medicine containing a LABA for any reason.

Immediate hypersensitivity reactions may occur with BROVANA. If signs occur, discontinue immediately and institute alternative therapy.

As with other inhaled beta2-agonists, BROVANA can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs, BROVANA should be discontinued immediately and alternative therapy instituted.

BROVANA, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, and/or symptoms. BROVANA should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension. Beta2-adrenergic agonists may produce significant hypokalemia in some patients.

As with other beta2-agonists, BROVANA, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because these agents may potentiate the action of adrenergic agonists on the cardiovascular system.

As with other beta2-agonists, BROVANA should be used with caution in patients treated with additional adrenergic drugs, non-potassium-sparing diuretics, and beta-blockers.

BROVANA, like all medicines containing sympathomimetic amines, should be used with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, and in patients who are unusually responsive to sympathomimetic amines.

Overall efficacy of BROVANA was maintained throughout the 12-week trial duration. Some tolerance to the bronchodilator effect of BROVANA was observed after 6 weeks of dosing (at the end of the dosing interval), although the FEV1 improvement remained statistically significant. This was not accompanied by other clinical manifestations of tolerance.

The five most common adverse events reported with frequency ≥2% in patients taking BROVANA, and occurring more frequently than in patients taking placebo, were pain (8% vs 5%), chest pain (7% vs 6%), back pain (6% vs 2%), diarrhea (6% vs 4%), and sinusitis (5% vs 4%).

BROVANA should not be swallowed as the intended effects on the lungs will not be obtained.  BROVANA is only for oral inhalation via a standard jet nebulizer connected to an air compressor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

For additional information, please see the full Prescribing Information including BOXED WARNING, and Medication Guide for BROVANA (arformoterol tartrate) Inhalation Solution, at


BROVANA® (arformoterol tartrate) Inhalation Solution is a long-acting beta2 -adrenergic agonist (LABA) indicated for the long-term, twice-daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. BROVANA is for use by nebulization only.

Important limitations: BROVANA is not indicated to treat acute deteriorations of COPD and is not indicated to treat asthma.